OKYO Pharma's Urcosimod Phase 2 Data Accepted for Presentation at Prestigious ASCRS Meeting
OKYO has more than doubled off its 52-week low of $0.902.
Summary
OKYO Pharma announced that efficacy and safety data from its Phase 2 study of urcosimod for neuropathic corneal pain has been accepted for presentation at the 2026 ASCRS Annual Meeting, providing external validation for its lead candidate.
Key Events · Product Development and Regulatory · OKYO
-
Phase 2 Data Accepted for ASCRS Presentation
An abstract detailing efficacy and safety results from the proof-of-concept Phase 2 study of urcosimod for neuropathic corneal pain (NCP) has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
-
Validation of Lead Candidate
This acceptance, following a competitive review process, provides external validation for urcosimod's potential as a novel therapeutic for NCP, building on previously announced positive efficacy signals.
-
Supports Upcoming Phase 2b/3 Trial
The presentation will share these results with leading ophthalmologists, advancing development efforts towards a planned 150-patient Phase 2b/3 multiple-dose study of urcosimod for NCP, expected to initiate in the first half of 2026, following recent FDA alignment on trial design on January 28, 2026.
Analysis · OKYO · Life Sciences
OKYO Pharma's announcement of its urcosimod Phase 2 data acceptance for presentation at the ASCRS Annual Meeting provides significant external validation for its lead candidate. This recognition from a prestigious scientific body reinforces the positive efficacy and safety signals previously observed in the proof-of-concept study for neuropathic corneal pain. The presentation will increase visibility among key ophthalmologists and supports the company's strategic path towards initiating a larger Phase 2b/3 trial in the first half of 2026, a plan recently aligned with the FDA. This event builds positive momentum for the company's clinical development efforts.
At the time of this filing, OKYO was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.7M. The 52-week trading range was $0.90 to $3.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.